Design of adult and paediatric studies investigating the efficacy and tolerability of ivacaftor [16, 17]. Design of adult and paediatric studies investigating.

Slides:

Advertisements

Similar presentations

Pulmonary response in sarcoidosis

Advertisements

Cardiovascular Impacts of High Frequency Chest Compression1

Effect of dornase alfa on inflammation and lung function: Potential role in the early treatment of cystic fibrosis Michael W. Konstan, Felix Ratjen

Bacterial contamination in the environment of hospitalised children with cystic fibrosis Agnès Ferroni, Aurélie Werkhauser-Bertrand, Muriel Le Bourgeois,

Effects of ivacaftor on severely ill patients with cystic fibrosis carrying a G551D mutation Helge Hebestreit, Annette Sauer-Heilborn, Rainald Fischer,

Advances in Cystic Fibrosis 2017

Zhumin Zhang, Suzanne M. Shoff, HuiChuan J. Lai

Efficacy and safety of ivacaftor in patients with cystic fibrosis and a non-G551D gating mutation Kris De Boeck, Anne Munck, Seth Walker, Albert Faro,

Cystic Fibrosis The Journal of Molecular Diagnostics

Advances in Cystic Fibrosis Perspectives From Orlando, 2016

Evaluating Effects of CFTR Modulation in Cystic Fibrosis

Correlation of excessive reactive oxygen species (ROS) production to clinical disease severity. Correlation of excessive reactive oxygen species (ROS)

Summary findings regarding the efficacy/safety profile across xanthines in chronic obstructive pulmonary disease patients. a) Combined plot of the change.

Distribution of forced expiratory volume in 1 s (FEV1) relative to Global Lung Function Initiative reference values (GLI2012) [10] expressed as FEV1 %

How does heart rate recovery after sub-maximal exercise correlate with maximal exercise testing in children with CF? Sarah P. Cohen, David M. Orenstein

Rescue of misfolded recoded cystic fibrosis transmembrane conductance regulator (CFTR) channels. a) Representative Western blot obtained from HEK293 cells.

Readthrough levels measured for the indicated cystic fibrosis transmembrane conductance regulator (CFTR) premature termination codon mutations, at basal.

High-resolution computed tomography (HRCT) features of interstitial lung abnormalities. a) HRCT of a 56-year-old patient whose mother died of idiopathic.

Measuring and improving respiratory outcomes in cystic fibrosis lung disease: Opportunities and challenges to therapy Edith T. Zemanick, J. Kirk Harris,

Immunostaining for lipid peroxidation product 4-hydroxy-2-nonenal (4-HNE) adduct in the lungs of smokers with and without chronic obstructive pulmonary.

Efficacy and safety of ivacaftor in patients with cystic fibrosis and a non-G551D gating mutation Kris De Boeck, Anne Munck, Seth Walker, Albert Faro,

D. Worlitzsch, C. Rintelen, K. Böhm, B. Wollschläger, N. Merkel, M

Pain in Children and Adults with Cystic Fibrosis: A Comparative Study

Function of recoded cystic fibrosis transmembrane conductance regulator (CFTR) channels. a) Representative recordings obtained from HEK293 cells expressing.

Maturation of recoded cystic fibrosis transmembrane conductance regulator (CFTR) channels. a) Representative Western blot obtained from HEK293 cells expressing.

Clinical outcomes in cystic fibrosis patients with Trichosporon respiratory infection Charles R. Esther, Rongpong Plongla, Alan Kerr, Feng-Chang Lin,

Flowchart showing the requirement for starting, documenting and evaluating the effect on quality of life (QoL) of interdisciplinary best supportive care.

Familial history of hereditary haemorrhagic telangiectasis (HHT) of the 29-yr-old patient (•) with HHT and severe pulmonary arterial hypertension (PAH).

Addressing Treatment Challenges in Cystic Fibrosis

Response to two identical exercise tests (T1 and T2) in 278 adults and 95 children with signs and symptoms of asthma but no definite diagnosis. Response.

The predictive potential of the sweat chloride test in cystic fibrosis patients with the G551D mutation Verena I. Seliger, David Rodman, Fredrick Van.

Schematic representation of breathing levels during positive expiratory pressure in an obstructed patient. Schematic representation of breathing levels.

Changes of a) spirometric, plethysmographic, and b) impedance data at 5 Hz induced by bronchodilator in flow limited (□) and nonflow limited (▓) patients.

UK Cystic Fibrosis Registry Annual Data Report 2017

A.H. Gifford Journal of Cystic Fibrosis

Change in lung clearance index (LCI) (mean±sd % change lung turnovers compared with baseline) based on modelled a, b) continuous and c, d) isolated pre-capillary.

Representative diaphragm electromyogram (EMG) tracings at rest (a and b) and during maximum voluntary ventilation (c and d) in a healthy subject (a and.

Correlation of sweat chloride and percent predicted FEV1 in cystic fibrosis patients treated with ivacaftor Meredith C. Fidler, Jack Beusmans, Paul Panorchan,

Changes in operating lung volumes are shown as ventilation increases with exercise in a) age-matched normal subjects (n = 25) and b) chronic obstructive.

Cystic fibrosis transmembrane conductance regulator gene variants are associated with autoimmune pancreatitis and slow response to steroid treatment

Chee Y. Ooi, Peter R. Durie Journal of Cystic Fibrosis

Novel concepts in evaluating antimicrobial therapy for bacterial lung infections in patients with cystic fibrosis Geraint B. Rogers, Lucas R. Hoffman,

Effect of ivacaftor in patients with advanced cystic fibrosis and a G551D-CFTR mutation: Safety and efficacy in an expanded access program in the United.

Trends in pathogens colonising the respiratory tract of adult patients with cystic fibrosis, 1985–2005 F.A. Millar, N.J. Simmonds, M.E. Hodson Journal.

James H. Hull, Rachel Garrod, Timothy B. Ho, Ronald K. Knight, John R

Time to disease progression or death in a) the whole Bosentan Use in Interstitial Lung Disease (BUILD)-1 study population and b) the subpopulation with.

Post-bronchodilator forced expiratory volume in 1 s (FEV1) to forced vital capacity (FVC) ratio in subjects aged >50 yrs. Post-bronchodilator forced expiratory.

Forest plot meta-analysis of the impact of long-acting β2-agonist (LABA)/long-acting muscarinic antagonist (LAMA) fixed-dose combinations on changes in.

D.F. Waterhouse, A.M. McLaughlin, C.G. Gallagher

The role of respiratory viruses in adult patients with cystic fibrosis receiving intravenous antibiotics for a pulmonary exacerbation C. Etherington,

Change in forced vital capacity (FVC) % predicted (% pred) per week from baseline in the CAPACITY 004 and 006 study comparing pirfenidone (2403 mg·day−1)

CFTR modulators and pregnancy: Our work has only just begun

Comparison between prediction equations from Wang et al

Lutz Goldbeck, Sven Zerrer, Tim G. Schmitz Journal of Cystic Fibrosis

Changes of CFTR functional measurements and clinical improvements in cystic fibrosis patients with non p.Gly551Asp gating mutations treated with ivacaftor

David Adeboyeku, Sandra Scott, Margaret E. Hodson

Impact of dose adjustment in case of adverse drug reaction (ADR; includes dose interruption and/or reduction). a) No dose adjustment and b) dose adjustment.

Mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) in Chinese patients with congenital bilateral absence of vas deferens Hongjun.

Receiver operating characteristic ROC curve of Lung Clearance Index (LCI)1/40, LCI1/30, LCI1/20, LCI1/10 and inverse forced expiratory volume in 1 s %

Relationship between a) forced expiratory flow at 25–75% of forced vital capacity (FVC) (FEF25–75%) and b) forced expiratory flow at 75% of FVC (FEF75%)

Cumulative mortality over 60 months in patients with α1-antitrypsin deficiency and an initial forced expiratory volume in 1 s

Global Initiative for Chronic Obstructive Lung Disease (GOLD) classification based on symptom and risk evaluation. a) GOLD model of symptom/risk evaluation.

Absence of a gender gap in survival

Ivacaftor restores G551D-cystic fibrosis transmembrane conductance regulator (CFTR) function in human bronchial epithelial (HBE) primary cell cultures.

Cystic fibrosis transmembrane conductance regulator (CFTR) gene mutations are categorised into six classes. Cystic fibrosis transmembrane conductance regulator.

Correlation of sweat chloride levels with cystic fibrosis transmembrane conductance regulator (CFTR) protein expression and function. Correlation of sweat.

Absolute change in forced expiratory volume in 1 s (FEV1) % pred over time in clinical trials with a) ivacaftor (IVA) in patients with at least one G551D.

Mean change from baseline in percentage predicted forced vital capacity (FVC) in the a) phase III CAPACITY [27] and b) ASCEND [14] studies. #: n=174; ¶:

Effects of reslizumab on lung function (forced expiratory volume in 1 s; FEV1) in Global Initiative for Asthma (GINA) Step 4 and 5 patients. Effects of.

Study design for ECLIPSE (VX-659 triple combination) and AURORA (VX-445 triple combination) phase 3 studies. Study design for ECLIPSE (VX-659 triple combination)

Presentation transcript:

Design of adult and paediatric studies investigating the efficacy and tolerability of ivacaftor [16, 17]. Design of adult and paediatric studies investigating the efficacy and tolerability of ivacaftor [16, 17]. PERSIST: An Open-Label Rollover Study to Evaluate the Safety and Efficacy of VX-770 in Cystic Fibrosis Patients; STRIVE: Evaluating the Efficacy and Safety of Treatment with VX-770 in CF patients with G551D Mutations; ENVISION: Evaluation of Efficacy and Safety of VX-770 in children six to eleven years old with CF; CFTR: cystic fibrosis transmembrane conductance regulator; FEV1: forced expiratory volume in 1 s; % pred: % predicted. Isabelle Sermet-Gaudelus Eur Respir Rev 2013;22:66-71 ©2013 by European Respiratory Society